Search
blinatumomab (Blincyto)
Indications:
- precursor B-cell acute lymphoblastic leukemia [1]
- Philadelphia chromosome-positive or negative [2]
- relapsed or refractory disease
- patients with minimal residual disease [2]
Adverse effects:
- fever, febrile neutropenia
- headache
- peripheral edema
- nausea
- hypokalaemia
- fatigue
- constipation
- diarrhea
- tremor
- cytokine release syndrome
- encephalopathy
Mechanism of action:
- bispecific antibody
- links CD19 on the surface of B-cell lymphoblasts with CD3 on T-cell lymphocytes
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
biological response modifier; immune factor; immunomodulator; biomodulator
bispecific antibody; bispecific monoclonal antibody
References
- FDA News Release. December 3, 2014.
FDA approves Blincyto to treat a rare form of acute
lymphoblastic leukemia.
First anti-CD19 drug to receive agency approval.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm
- Ingram I.
Blincyto OK'd for MRD-Positive Acute Lymphoblastic Leukemia.
Residual disease undetectable in 70 of 86 patients treated.
MedPage Today. March 29, 2018
https://www.medpagetoday.com/hematologyoncology/leukemia/72073
- FDA News Release. March 29, 2018
FDA expands approval of Blincyto for treatment of a type of
leukemia in patients who have a certain risk factor for relapse.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm603151.htm
- Brown PA, Ji L, Xu X et al
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs
Chemotherapy on Disease-Free Survival in Children, Adolescents,and
Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia.
A Randomized Clinical Trial.
JAMA. 2021;325(9):833-842
PMID: 33651090
https://jamanetwork.com/journals/jama/fullarticle/2776879
- Locatelli F, Zugmaier G, Rizzari C et al
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among
Children With High-risk First-Relapse B-Cell Acute Lymphoblastic
Leukemia. A Randomized Clinical Trial.
JAMA. 2021;325(9):843-854.
PMID: 33651091
https://jamanetwork.com/journals/jama/fullarticle/2776881
- Shukla N, Sulis ML
Blinatumomab for Treatment of Children With High-risk Relapsed
B-Cell Acute Lymphoblastic Leukemia.
JAMA. 2021;325(9):830-832
PMID: 33651075
https://jamanetwork.com/journals/jama/fullarticle/2776860
- Kinnaman M
Blinatumomab a Game Changer for B-cell Precursor ALL.
Bispecific antibody constructs often compared with CAR T cells.
MedPage Today. ASCO Reading Room. April 9, 2021
https://www.medpagetoday.com/reading-room/asco/immunotherapy/91982
- Lussan F, Gritti G, Rambaldi A et al
Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-
Redirected Bispecific Antibodies.
J Clin Oncol 2021. 39(5):444-455. Feb 10.
PMID: 33434063
https://ascopubs.org/doi/10.1200/JCO.20.01564